Comparative polar and lipid plasma metabolomics differentiate KSHV infection and disease states.

Biomarkers HIV KSHV Kaposi sarcoma Metabolite profiling Metabolomics

Journal

Cancer & metabolism
ISSN: 2049-3002
Titre abrégé: Cancer Metab
Pays: England
ID NLM: 101607582

Informations de publication

Date de publication:
31 Aug 2023
Historique:
received: 12 04 2023
accepted: 22 08 2023
medline: 1 9 2023
pubmed: 1 9 2023
entrez: 31 8 2023
Statut: epublish

Résumé

Kaposi sarcoma (KS) is a neoplastic disease etiologically associated with infection by the Kaposi sarcoma-associated herpesvirus (KSHV). KS manifests primarily as cutaneous lesions in individuals due to either age (classical KS), HIV infection (epidemic KS), or tissue rejection preventatives in transplantation (iatrogenic KS) but can also occur in individuals, predominantly in sub-Saharan Africa (SSA), lacking any obvious immune suppression (endemic KS). The high endemicity of KSHV and human immunodeficiency virus-1 (HIV) co-infection in Africa results in KS being one of the top 5 cancers there. As with most viral cancers, infection with KSHV alone is insufficient to induce tumorigenesis. Indeed, KSHV infection of primary human endothelial cell cultures, even at high levels, is rarely associated with long-term culture, transformation, or growth deregulation, yet infection in vivo is sustained for life. Investigations of immune mediators that distinguish KSHV infection, KSHV/HIV co-infection, and symptomatic KS disease have yet to reveal consistent correlates of protection against or progression to KS. In addition to viral infection, it is plausible that pathogenesis also requires an immunological and metabolic environment permissive to the abnormal endothelial cell growth evident in KS tumors. In this study, we explored whether plasma metabolomes could differentiate asymptomatic KSHV-infected individuals with or without HIV co-infection and symptomatic KS from each other. To investigate how metabolic changes may correlate with co-infections and tumorigenesis, plasma samples derived from KSHV seropositive sub-Saharan African subjects in three groups, (A) asymptomatic (lacking neoplastic disease) with KSHV infection only, (B) asymptomatic co-infected with KSHV and HIV, and (C) symptomatic with clinically diagnosed KS, were subjected to analysis of lipid and polar metabolite profiles RESULTS: Polar and nonpolar plasma metabolic differentials were evident in both comparisons. Integration of the metabolic findings with our previously reported KS transcriptomics data suggests dysregulation of amino acid/urea cycle and purine metabolic pathways, in concert with viral infection in KS disease progression. This study is, to our knowledge, the first to report human plasma metabolic differentials between in vivo KSHV infection and co-infection with HIV, as well as differentials between co-infection and epidemic KS.

Sections du résumé

BACKGROUND BACKGROUND
Kaposi sarcoma (KS) is a neoplastic disease etiologically associated with infection by the Kaposi sarcoma-associated herpesvirus (KSHV). KS manifests primarily as cutaneous lesions in individuals due to either age (classical KS), HIV infection (epidemic KS), or tissue rejection preventatives in transplantation (iatrogenic KS) but can also occur in individuals, predominantly in sub-Saharan Africa (SSA), lacking any obvious immune suppression (endemic KS). The high endemicity of KSHV and human immunodeficiency virus-1 (HIV) co-infection in Africa results in KS being one of the top 5 cancers there. As with most viral cancers, infection with KSHV alone is insufficient to induce tumorigenesis. Indeed, KSHV infection of primary human endothelial cell cultures, even at high levels, is rarely associated with long-term culture, transformation, or growth deregulation, yet infection in vivo is sustained for life. Investigations of immune mediators that distinguish KSHV infection, KSHV/HIV co-infection, and symptomatic KS disease have yet to reveal consistent correlates of protection against or progression to KS. In addition to viral infection, it is plausible that pathogenesis also requires an immunological and metabolic environment permissive to the abnormal endothelial cell growth evident in KS tumors. In this study, we explored whether plasma metabolomes could differentiate asymptomatic KSHV-infected individuals with or without HIV co-infection and symptomatic KS from each other.
METHODS METHODS
To investigate how metabolic changes may correlate with co-infections and tumorigenesis, plasma samples derived from KSHV seropositive sub-Saharan African subjects in three groups, (A) asymptomatic (lacking neoplastic disease) with KSHV infection only, (B) asymptomatic co-infected with KSHV and HIV, and (C) symptomatic with clinically diagnosed KS, were subjected to analysis of lipid and polar metabolite profiles RESULTS: Polar and nonpolar plasma metabolic differentials were evident in both comparisons. Integration of the metabolic findings with our previously reported KS transcriptomics data suggests dysregulation of amino acid/urea cycle and purine metabolic pathways, in concert with viral infection in KS disease progression.
CONCLUSIONS CONCLUSIONS
This study is, to our knowledge, the first to report human plasma metabolic differentials between in vivo KSHV infection and co-infection with HIV, as well as differentials between co-infection and epidemic KS.

Identifiants

pubmed: 37653396
doi: 10.1186/s40170-023-00316-0
pii: 10.1186/s40170-023-00316-0
pmc: PMC10470137
doi:

Types de publication

Journal Article

Langues

eng

Pagination

13

Informations de copyright

© 2023. BioMed Central Ltd., part of Springer Nature.

Références

Nature. 2021 Mar;591(7851):645-651
pubmed: 33589820
Am J Epidemiol. 1998 Feb 1;147(3):217-21
pubmed: 9482495
Nucleic Acids Res. 2018 Jan 4;46(D1):D608-D617
pubmed: 29140435
PLoS One. 2011;6(5):e19901
pubmed: 21625475
AIDS Res Hum Retroviruses. 2021 May;37(5):368-372
pubmed: 33386064
Front Cell Infect Microbiol. 2021 Aug 30;11:725284
pubmed: 34527604
Proc Natl Acad Sci U S A. 2010 Jun 8;107(23):10696-701
pubmed: 20498071
J Virol. 2017 Apr 28;91(10):
pubmed: 28275189
Cell. 2015 Sep 10;162(6):1229-41
pubmed: 26321679
Gene. 2019 May 25;698:120-128
pubmed: 30849534
Lancet. 1990 Jan 20;335(8682):168-9
pubmed: 1967458
Arterioscler Thromb Vasc Biol. 2017 Jun;37(6):1241-1249
pubmed: 28408375
Tumour Virus Res. 2023 Jun;15:200259
pubmed: 36863485
Life Sci. 2021 Mar 15;269:118968
pubmed: 33417959
Biol Res Nurs. 2018 Mar;20(2):227-236
pubmed: 29258398
Front Immunol. 2022 Jan 12;12:742736
pubmed: 35095835
AIDS. 2015 Jan 2;29(1):43-51
pubmed: 25387317
J Clin Oncol. 2014 Feb 10;32(5):409-14
pubmed: 24378415
Anal Chem. 2009 Dec 15;81(24):10038-48
pubmed: 19928838
N Engl J Med. 1995 May 4;332(18):1181-5
pubmed: 7700310
Sci Rep. 2016 Dec 13;6:38881
pubmed: 27958387
PLoS Pathog. 2015 Jul 21;11(7):e1005052
pubmed: 26197457
PLoS Pathog. 2011 Jul;7(7):e1002124
pubmed: 21779165
Oncotarget. 2020 Apr 28;11(17):1556-1572
pubmed: 32391124
Exp Mol Med. 2020 Feb;52(2):192-203
pubmed: 32060354
Sci Adv. 2021 May 19;7(21):
pubmed: 34138729
Curr Opin Virol. 2016 Aug;19:45-9
pubmed: 27434732
Front Oncol. 2020 Oct 26;10:589508
pubmed: 33194749
J Infect Dis. 2019 Apr 8;219(8):1318-1328
pubmed: 30452681
PLoS Pathog. 2012;8(8):e1002866
pubmed: 22916018
Cells. 2019 Jul 16;8(7):
pubmed: 31315173
Cancers (Basel). 2021 Nov 14;13(22):
pubmed: 34830846
Nucleic Acids Res. 2021 Jul 2;49(W1):W388-W396
pubmed: 34019663
Antioxidants (Basel). 2022 Dec 30;12(1):
pubmed: 36670946
Nat Rev Dis Primers. 2019 Jan 31;5(1):9
pubmed: 30705286
Apoptosis. 2021 Aug;26(7-8):385-414
pubmed: 34236569
Cancer. 2017 Oct 15;123(20):4066-4074
pubmed: 28640361
Nucleic Acids Res. 2018 Jul 2;46(W1):W486-W494
pubmed: 29762782
Trends Cell Biol. 2023 Nov;33(11):950-966
pubmed: 36967301
J Exp Med. 2021 Jan 4;218(1):
pubmed: 33601415
Semin Oncol. 2015 Apr;42(2):247-57
pubmed: 25843729
Nat Methods. 2018 Jan;15(1):53-56
pubmed: 29176591
J Int AIDS Soc. 2021 Jan;24(1):e25658
pubmed: 33405281
Crit Rev Biochem Mol Biol. 2021 Oct;56(5):500-509
pubmed: 34130564
PLoS Pathog. 2020 Jul 24;16(7):e1008681
pubmed: 32706839
Cancers (Basel). 2020 Jun 16;12(6):
pubmed: 32560243
Nat Rev Cancer. 2010 Oct;10(10):707-19
pubmed: 20865011
PLoS Pathog. 2018 Jan 19;14(1):e1006844
pubmed: 29352292
Science. 1994 Dec 16;266(5192):1865-9
pubmed: 7997879
J Am Acad Dermatol. 1981 Oct;5(4):468-71
pubmed: 7287964
Anal Chem. 2012 May 15;84(10):4396-403
pubmed: 22497521

Auteurs

Sara R Privatt (SR)

School of Biological Sciences, University of Nebraska-Lincoln, Lincoln, NE, USA.
Department of Interdisciplinary Oncology, Louisiana State University Health Sciences Center, New Orleans, LA, USA.

Camila Pereira Braga (CP)

Department of Biochemistry, University of Nebraska-Lincoln, Lincoln, NE, USA.

Alicia Johnson (A)

Department of Biochemistry, University of Nebraska-Lincoln, Lincoln, NE, USA.
Redox Biology Center, University of Nebraska-Lincoln, Lincoln, NE, USA.

Salum J Lidenge (SJ)

Ocean Road Cancer Institute, Dar Es Salaam, Tanzania.
Muhimbili University of Health and Allied Sciences, Dar Es Salaam, Tanzania.

Luke Berry (L)

Department of Biochemistry, University of Nebraska-Lincoln, Lincoln, NE, USA.
Redox Biology Center, University of Nebraska-Lincoln, Lincoln, NE, USA.

John R Ngowi (JR)

Ocean Road Cancer Institute, Dar Es Salaam, Tanzania.

Owen Ngalamika (O)

Dermatology and Venereology Section, Adult Hospital of the University Teaching Hospitals, University of Zambia School of Medicine, Lusaka, Zambia.

Andrew G Chapple (AG)

Department of Interdisciplinary Oncology, Louisiana State University Health Sciences Center, New Orleans, LA, USA.

Julius Mwaiselage (J)

Ocean Road Cancer Institute, Dar Es Salaam, Tanzania.
Muhimbili University of Health and Allied Sciences, Dar Es Salaam, Tanzania.

Charles Wood (C)

School of Biological Sciences, University of Nebraska-Lincoln, Lincoln, NE, USA.
Department of Interdisciplinary Oncology, Louisiana State University Health Sciences Center, New Orleans, LA, USA.

John T West (JT)

Department of Interdisciplinary Oncology, Louisiana State University Health Sciences Center, New Orleans, LA, USA. jwest6@lsuhsc.edu.

Jiri Adamec (J)

Department of Interdisciplinary Oncology, Louisiana State University Health Sciences Center, New Orleans, LA, USA. jadame@lsuhsc.edu.

Classifications MeSH